The purpose of this study is to determine the effectiveness of adjunctive treatment of pregabalin with \[S,S\]-Reboxetine against pregabalin monotherapy in patients with PHN
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
136
\[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
The numerical pain intensity rating scale is used to assess pain and a change from baseline in pain score for week 10 will be calculated
Time frame: Week 10
The mean endpoint (week 10) sleep interference score change from baseline
Time frame: Week 10
Analysis of the Medical Outcomes Study Sleep Scale
Time frame: Week 10
Analysis of the Patient Global Impression of Change
Time frame: Week 10
Analysis of the Neuropathic Pain Symptom Inventory
Time frame: Week 10
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Huntsville, Alabama, United States
Pfizer Investigational Site
Gilbert, Arizona, United States
Pfizer Investigational Site
North Dartmouth, Massachusetts, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Amherst, New York, United States
Pfizer Investigational Site
Orchard Park, New York, United States
Pfizer Investigational Site
Kettering, Ohio, United States
Pfizer Investigational Site
Vienna, Austria
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Calgary, Alberta, Canada
...and 73 more locations